CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 213 enrolled
Drug / intervention
Panitumumab + Chemotherapyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01732783
NCT01732783N/ACompleted
CompareCT.gov

Prospective Observational Cohort Study to Describe the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type RAS Metastatic Colorectal Cancer

Amgen·observational·Posted Nov 26, 2012·Updated Nov 8, 2022

In Brief

An observational study evaluating Panitumumab + Chemotherapy for Wild-type RAS Metastatic Colorectal Cancer. Completed, enrolled 213 participants.

Detailed Summary

The primary objective was to describe the pattern of use of panitumumab (Vectibix®) in combination with chemotherapy in patients with wild-type rat sarcoma viral oncogene homolog (RAS) metastatic colorectal cancer (mCRC): as first-line treatment in combination with FOLFOX or FOLFIRI or second-line treatment in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsWild-type RAS Metastatic Colorectal Cancer
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 26, 2012
Enrollment StartDec 10, 2012
Primary CompletionNov 30, 2016
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 13.6 years ago

Interventions

Panitumumab + Chemotherapyother

Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.